NRG Oncology Appoints Kati Stoermer for New Executive Director Role

PHILADELPHIA, PA — NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN), has appointed Kati Stoermer as the organization’s Executive Director. In this new role, Stoermer will be providing oversight and management of the NRG Oncology operational activities coordinated by staff located in Philadelphia and Pittsburgh. She will also be coordinating with the organization’s Statistical and Data Management Center and the group’s Biospecimen Bank.

“The newly created role of NRG Executive Director will further advance NRG Oncology’s mission of improving the lives of cancer patients through the conduct of our clinical trials,” stated Walter J. Curran Jr., MD, an NRG Oncology Group Chair and Executive Director of the Emory University Winship Cancer Institute in Atlanta, Georgia.

Ms. Stoermer joins NRG Oncology following four years serving as the Director of Research Operations for the Department of Veteran Affairs in Ann Arbor (MI) Healthcare System. Prior to her tenure at the Department of Veteran Affairs, Ms. Stoermer was an Associate Director of Administration for SWOG, another NCTN network group. At SWOG, Ms. Stoermer conceptualized and piloted centrally-provided coverage analyses for SWOG trials that have been adopted widely within the NCTN and have recently expanded through a partnership with the NCI and the American Society of Clinical Oncology (ASCO).

Ms. Stoermer’s extensive experience within the NCTN program and her noted accomplishments in cancer care administration will positively influence NRG Oncology’s ability to ensure that its NCTN research activities, policies, and operational function support align with the organization’s research mission.

“Cancer touches everyone in some way, and I am delighted to join NRG Oncology and work with our researchers and members to help improve the lives of patients with cancer,” added Ms. Stoermer.

Kati Stoermer’s appointment was recently announced to the organization’s membership at NRG Oncology’s Semiannual Meeting January 25-27th in Phoenix Arizona.

www.nrgoncology.org

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the
lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the NSABP Foundation, the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.